Pegylated interferon α-2b

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

41 competitors in TED

#DrugCompanyPhaseTrials

1

Alecensa

Roche

Approved

12

Scemblix

Novartis

Approved

13

Medrol

Pfizer

Phase 3

24

Golytely

Bayer

Phase 3

15

Fludara

Sanofi

Phase 2

36

Eliquis

Bristol-Myers Squibb

Phase 2

37

Venclexta

AbbVie

Phase 2

28

Epkinly

Genmab

Phase 2

19

Rituxan

Roche

Phase 2

110

Gazyva

Roche

Phase 2

1Show 26 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Chronic Hepatitis6 trials

Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)

Completed·Merck & Co.··NCT00725751·353 enrolled

PegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (P04498/MK-4031-278)

Completed·Merck & Co.·Phase 3·NCT00371761·25 enrolled

Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment-Naive

Completed·BBausch Health Americas, Inc.·Phase 3·NCT00230958·900 enrolled

Show 3 more trials

Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)

Completed·Merck & Co.·Phase 3·NCT00708500·404 enrolled

A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)

Completed·Merck & Co.·Phase 2·NCT01710501·87 enrolled

Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED)

Completed·Merck & Co.·Phase 4·NCT00686777·75 enrolled

Essential Thrombocythemia2 trials

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT04226950·40 enrolled

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia

Unknown status·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05395507·194 enrolled

Hepatitis C2 trials

The SIM-SOF Trial for Hepatitis C

Completed·CCenter For Hepatitis C, Atlanta, GA·Phase 4·NCT02168361·93 enrolled

Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)

Completed·Merck & Co.·Phase 3·NCT00686517·130 enrolled

TED2 trials

Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05870475·94 enrolled

Nilotinib Plus Pegylated Interferon-α2b in CML

Terminated·AAmsterdam UMC, location VUmc·Phase 2·NCT01866553·20 enrolled

COVID-191 trial

Pegylated Interferon - α2b With SARSCoV- 2 (COVID-19)

Terminated·ZZydus Lifesciences Limited·Phase 2·NCT04480138·7 enrolled

9 more indications

Chronic Myelogenous Leukemia1 trial

Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)

Terminated·Merck & Co.·Phase 2/3·NCT03547154·344 enrolled

Melanoma1 trial

A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)

Completed·Merck & Co.·Phase 2·NCT02155322·33 enrolled

Leukemia1 trial

Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma

Completed·UUniversity of Miami·Phase 2·NCT02737046·15 enrolled

Treatment1 trial

A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3

Completed·KKirby Institute·Phase 4·NCT01364090·93 enrolled

Lymphoma1 trial

Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma

Unknown status·HHuiqiang Huang·Phase 2·NCT04246359·52 enrolled

Hepatitis B1 trial

Combination Treatment of NAs and Peg IFN α-2b for Hepatitis B Related, Compensatory Cirrhosis Patients

Unknown status·SSun Yat-sen University·Phase 2·NCT03969017·84 enrolled

CTCL1 trial

Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL

Terminated·NNorthwestern University·N/A·NCT00724061·7 enrolled

Metastatic Melanoma1 trial

Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma

Completed·UUniversity Hospital Schleswig-Holstein·Phase 2·NCT00623402·55 enrolled

Chronic Hepatitis b1 trial

Safety and Efficacy of Sequential Treatment With a PD-1 Antibody and Pegylated Interferon-α in Nucleos(t)Ide Analogue-Suppressed Patients With Chronic Hepatitis B

Not yet recruiting·BBeijing 302 Hospital·Preclinical·NCT07809165·60 enrolled

Details

Drug Info

Related News